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Abstract 
Aims: Analyze the clinical applicability of glucose metabolism indexes and continuous glucose monitoring data on 
the qualitative diagnosis of insulinoma.
Methods: Involve 22 patients with insulinoma (insulinoma group), 11 patients with hypoglycemia (hypoglycemia 
group) and 31 people with normal glucose tolerance (control group). HbA1c, fasting blood glucose (FBG), insulin 
(FINS) and C-peptide (FCP) was tested. Using CGMS to monitor the blood glucose for three consecutive days and 
selecting the monitoring data of 24 h thereof, figuring out, with the aid of EasyGV Version 9.0, the mean glucose (MG), 
the standard deviation (SD) of blood glucose, CONGA (continuous overall net glycemic action), J-Index, LI (Lability 
Index), LBGI (Low Blood Glucose Index), HBGI (High Blood Glucose Index), GRADE (glycaemic risk assessment diabetes 
equation), MAGE (mean aplitude of glycaemic excursions), M value, MAG (mean absolute glucose).
Results: (1) FBG and LBG of insulinoma group are lower than those of control group and those of hypoglycemia 
group while FINS and FCP of insulinoma group are markedly higher than those of the other two groups; (2) the MG 
and CONGA of insulinoma group are lower than those of control group and its indexes like ST, LI, LBGI, GRADE, MAGE, 
M value and MAG are higher than those of control group; there are differences between the indexes of insulinoma 
group and those of hypoglycemia group in CONGA (lower than that of hypoglycemia group), LBGI (higher than that 
of hypoglycemia group), and M value (higher than that of hypoglycemia group). By drawing the ROC curve and calcu-
lating Youden index, the cut-off values of LBGI, M value, CONGA are respectively as 4.06, 7.79, 4.38, and the best index 
of differential diagnosis is LBGI.
Conclusion: Continuous glucose monitoring data can be used to diagnose insulinoma and blood glucose fluctua-
tion indicators such as LBGI, M value, CONGA might be useful to identify insulinoma.
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Background
Insulinoma is the most common functional islet cell 
tumor of which the most prominent characteristic is the 
severe status of hypoglycemia caused by improper insulin 
secretion. It is a common cause of organic hypoglycemia 
of which the symptoms are diverse and there is a lack 
of uniqueness [1]. If the nervous system gradually gets 
accustomed to the chronical hypoglycemia, there will 
appear asymptomatic hypoglycemia [2], which shall bring 
about high rates of missed diagnosis and misdiagnosis. 
More than 50% of the patients are diagnosed to have suf-
fered from it for over five years [3].
The continuous glucose monitoring system is capable 
of providing the information about blood glucose in all 
day consecutively and has unique advantages in assess-
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hypoglycemia. Combining with other clinical glucose 
metabolism indexes, it can be used to discuss how useful 




The study has selected 22 patients who, hospitalized 
in the endocrinology wards in 301 hospital from May 
2011 to April 2014, were diagnosed with insulinoma and 
examined by the continuous glucose monitoring system 
(the insulinoma group), 8 of the patients are men and 14 
women with their age ranging from 22 to 71. All of them 
underwent surgery and pathologically confirmed insu-
linoma. 11 patients with non-islet cell tumor who were 
hospitalized because of reactive hypoglycemia during the 
same period (the hypoglycemia group), there are six men 
and five women ranging from 39 to 73 years old. Patients 
with diabetes, any other organic pathology or drug-
induced hypoglycemia were excluded; reactive hypogly-
cemia is defined when recurrent episodes of symptomatic 
hypoglycemia occur 2–4 h after a high carbohydrate meal 
(or oral glucose load),and the result of 72-h fasting test is 
negative; 31 people with normal glucose metabolism (the 
control group) on the basis of the diagnosis standards of 
diabetes under WHO and for the purpose of the glucose 
tolerance experiment, among whom there 15 men and 
16 women ranging from 20 to 70 years old. All subjects 
are free of any severe hepatorenal damage or other seri-
ous stress state such as cardiac insufficiency, trauma, 
pregnancy, tumor, and infectious diseases. The study 
was conducted in accordance with the principles of the 
Declaration of Helsinki and approved by the Ethics Com-
mittee of the Chinese PLA General Hospital. Written 
informed consent was obtained from each patient before 
enrollment.
Methods
Collection of clinical data Take a detailed record of all 
subjects’ age, sex, BMI, course of disease, as well as the 
biochemical indicators including HbA1c, fasting blood 
glucose, uric acid, and blood lipid.
Continuous glucose monitoring system and  collection 
of  data All monitoring work is developed with the 
CGMS from Medtronic Inc. Implant the probe of the 
CGMS into the abdominal subcutaneous tissue and 
monitor the glucose concentration of the interstitial fluid 
of subcutaneous tissues in 72 h. Take down a MG every 
5 min and 288 blood glucose values within 24 h. In the 
meanwhile, use the Bai’anyi blood glucometer from Bayer 
company to determine the blood glucose of the fingertip 
capillaries for at least 4 times a day and enter the results 
into CGMS for correcting. Strenuous exercise or shower 
is not allowed during the period of glucose monitoring.
Assessment of glucose level and the fluctuation parameters 
of it The CGMS software can offer the amplitude of glu-
cose fluctuation (the highest and lowest numbers of blood 
glucose), the mean blood glucose (MBG), the standard 
deviation of blood glucose (SD) and the bigger the SD is, 
the bigger the difference there will be between the aver-
age and mean blood glucose, and the bigger the amplitude 
of glucose fluctuation will be; by setting the capping and 
floor of the blood glucose (here we assume the capping is 
10.0 mmol/L and the floor 2.8 mmol/L), the proportion of 
time distribution beyond the capping/floor as well as the 
residence time can be obtained; the times of blood glu-
cose fluctuation in all day and the times of hyperglycemia/
hypoglycemia fluctuation. The software counts the blood 
glucose fluctuating for more half an hour as one time. In 
addition, calculating the mean glucose (MG), the standard 
deviation of glucose (SD), CONGA (continuous overall 
net glycemia action), J-Index, LI (Liability Index), LBGI 
(Low Blood Glucose Index), HBGI (High Blood Glucose 
Index), GRADE (glycaemic risk assessment diabetes equa-
tion), MAGE (mean aplitude of glycaemic excursions), M 
value, MAG (mean absolute glucose).
Statistical methods
The normal distributions of the measurement data are 
represented by x ± s, the inter-group comparison is ana-
lyzed by t test or variance, the comparison of non-normal 
distribution data adopts the non-parametric test. ROC 
curves are used to compare the diagnostic performance 
of some indexes. Statistical treatment of the data adopts 
SPSS19.O with P < 0.05 as the statistical deviation.
Results
Comparison of the general data of each group
The general data of the insulinoma group, the hypogly-
cemia group and the control group (see Table  1). The 
inter-group differences of the course of diseases and the 
BMI are of statistical significance, and the differences of 
other indexes (age, blood pressure, blood lipid, uric acid) 
have no such significance. Patients in the insulinoma 
group have longer course of disease than patients in the 
hypoglycemia group do, with the longest course reach-
ing 20  years, and their BMI are higher than patients in 
the hypoglycemia group and people in the control group 
with the average value of 28.44 ± 4.49 kg/m2.
Comparison of glucose metabolism indexes of three 
groups
Compare the glucose metabolism indexes of three groups 
and find out that there are marked differences in the 
Page 3 of 7Gu et al. Diabetol Metab Syndr  (2017) 9:17 
fasting blood glucose, the lowest blood glucose in all day, 
the fasting insulin and the fasting C-peptide. Make pair-
wise comparison of those indexes and discover that the 
fasting blood glucose and the lowest blood glucose in all 
day of the insulinoma group are lower than those of the 
control group and the hypoglycemia group, while the 
fasting insulin and the fasting C-peptide are higher than 
those of the other two groups. All the differences are of 
statistical significance (see Table 2).
Comparison of occurrence of hypoglycemia of patients 
in the insulinoma group and patients in the hypoglycemia 
group
Comparing with patients in the hypoglycemia group, the 
patients with insulinoma tend to suffer more hypoglyce-
mia, with longer course and more severe consequences: 
the insulinoma group has more hypoglycemia fluctua-
tions, lower number of the lowest blood glucose, more 
percentage beyond the floor set for glucose and longer 
course. Within 24  h, there 11 patients (50.0%) in the 
insulinoma group suffer hypoglycemia, averagely every 
110  min the blood glucose of one person is less than 
2.8 mmol/L, accounting for 7.67%; whereas in the hypo-
glycemia group there are only two people (15.4%) suffer-
ing hypoglycemia, one person every 20 min (see Table 3).
Comparison of post‑CGMS glucose variation indexes 
of patients in three groups
The comparison of inter-group skewed distribution data 
adopts the rank-sum test and there are remarkable dif-
ferences among the groups of other indexes with the 
exception of J-Index and HBGI (see Table 4). Then make 
pairwise comparison of indexes with inter-group dif-
ferences (see Tables  5, 6). Comparing with the control 
group in the rank means of each index, the insulinoma 
group has lower MG and GONGA, higher SD, LI, LBGI, 
Table 1 Comparison of general data of patients in three groups
BMI Body Mass Index, SBP systolic blood pressure, DBP diastolic blood pressure, UA uric acid, TG triglycerides, CHO total cholesterol, HDL high-density lipoprotein 
cholesterol, LDL low-density lipoprotein cholesterol
*P < 0.05
Variables Insulinoma group (44) Hypoglycemia group (26) Control group (31) P value
Sex (M/F) 16/28 14/12 15/16
Age 50.59 ± 13.2 55.64 ± 12.6 53.23 ± 11.9 0.302
Course 6.43 ± 6.94* 1.62 ± 2.24 – 0.006
BMI 28.44 ± 4.49* 24.54 ± 3.75 22.7 ± 2.6 0.019
SBP 129.32 ± 14.35 138.0 ± 14.21 133.0 ± 14.18 0.11
DBP 80.64 ± 10.45 77.91 ± 8.32 78.0 ± 7.45 0.458
UA 303.02 ± 63.77 273.87 ± 82.9 282.32 ± 9.52 0.30
TG 1.41 ± 1.05 1.20 ± 0.50 1.15 ± 0.87 0.55
CHO 4.16 ± 0.92 4.16 ± 0.80 4.46 ± 0.8 0.99
HDL 1.16 ± 0.41 1.30 ± 0.55 1.41 ± 0.61 0.46
LDL 2.46 ± 0.8 2.4 ± 0.68 2.43 ± 0.78 0.85
Table 2 Comparison of glucose metabolism indexes of three groups
HBG high blood glucose, LBG low blood glucose, MBG mean blood glucose, SD standard deviation, HbA1c glalycosylated hemoglobin A1c, FBG fasting blood glucose, 
FINS fasting insulin, FCP fasting C-peptide, IRI Insulin Release Index
*P < 0.05
Variables Insulinoma group (n = 44) Hypoglycemia group (n = 26) Control group (n = 31) F value P value
HBG (mmol/L) 9.00 ± 3.10 9.65 ± 4.47 8.27 ± 1.51 0.95 0.628
LBG (mmol/L)* 2.76 ± 0.92 3.93 ± 0.75 4.67 ± 0.63 9.74 0.001
MBG (mmol/L) 5.10 ± 1.20 5.99 ± 1.63 5.83 ± 0.66 2.86 0.085
SD 1.46 ± 0.79 1.25 ± 1.15 0.92 ± 0.28 1.03 0.526
HbA1c (%) 4.97 ± 0.50 5.27 ± 0.39 5.52 ± 0.21 2.14 0.101
FBG (mmol/L)* 3.37 ± 1.29 4.83 ± 0.40 4.74 ± 0.37 14.72 0.000
FINS (mU/L)* 22.63 ± 15.09 8.04 ± 6.19 8.60 ± 3.60 10.72 0.000
FCP (ng/mL)* 3.17 ± 1.18 2.17 ± 1.04 2.23 ± 0.69 5.07 0.011
IRI* 0.45 ± 0.36 0.09 ± 0.07 0.10 ± 0.05 12.80 0.000
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Table 3 Comparison of occurrence of hypoglycemia of patients in the insulinoma group and patients in the hypoglyce-
mia group
*P < 0.05
Variables Insulinoma group (n = 44) Hypoglycemia group (n = 26) P value
Times of glucose fluctuation* 2.68 ± 2.51 0.45 ± 0.93 0.001
Times of hypoglycemia fluctuation* 2.23 ± 2.18 0 ± 0.00 0.000
Lowest glucose in all day* 2.76 ± 0.92 3.93 ± 0.75 0.001
Lowest glucose at night* 3.17 ± 1.17 4.6 ± 0.94 0.001
Proportion beyond the capping 2.23 ± 5.54 3.55 ± 8.43 0.593
Proportion beyond the floor* 7.56 ± 10.37 0.01 ± 0.03 0.003
Time beyond the capping 32.05 ± 79 45.45 ± 104.37 0.683
Time beyond the floor* 108.86 ± 149.7 0 ± 0.00 0.003
Table 4 Comparison of post-CGMS glucose variation indexes of patients in three groups
MBG mean blood glucose, SD standard deviation, CONGA continuous overall net glycemic action, LI lability index, LBGI Low Blood Glucose Index, HBGI High Blood 
Glucose Index, GRADE glycaemic risk assessment diabetes equation, MAGE mean aplitude of glycaemic excursions, MAG mean absolute glucose
*P < 0.05
Variables Insulinoma group (n = 44) Hypoglycemia group (n = 26) Control group (n = 31) Chi square P value
MBG* 23.59 34.62 40.06 9.53 0.009
SD* 42.23 34.31 26.97 8.16 0.017
CONGA* 20.00 37.62 41.35 16.67 0.000
LI* 45.32 31.46 25.97 13.26 0.001
J-Index 29.59 36.38 35.06 1.41 0.494
LBGI* 49.68 31.38 22.90 25.24 0.000
HBGI 34.25 37.92 31.11 1.20 0.548
GRADE* 46.61 30.77 25.34 16.15 0.000
MAGE* 41.32 33.17 27.03 7.35 0.025
M value* 49.09 33.92 22.26 25.15 0.000
MAG* 49.36 34.85 21.68 26.85 0.000
Table 5 Pairwise comparison of CGMS indexes
MBG mean blood glucose, SD standard deviation, CONGA continuous overall 
net glycemic action, LI Lability Index, LBGI Low Blood Glucose Index, GRADE 
glycaemic risk assessment diabetes equation, MAGE mean aplitude of glycaemic 
excursions, MAG mean absolute glucose
*P < 0.05
Variables Insulinoma group Control group Z value P value
MBG* 19.27 32.48 −3.069 0.002
SD* 34.41 21.74 −2.942 0.003
CONGA* 16.95 34.13 −3.989 0.000
LI* 36.27 20.42 −3.682 0.000
LBGI* 39.23 18.32 −4.856 0.000
GRADE* 37.27 19.71 −4.084 0.000
MAGE* 34.00 22.03 −2.780 0.005
M value* 39.23 18.32 −4.856 0.000
MAG* 40.00 17.77 −5.163 0.000
Table 6 Pairwise comparison of CGMS indexes
MBG mean blood glucose, SD standard deviation, CONGA continuous overall 
net glycemic action, LI Lability Index, LBGI Low Blood Glucose Index, GRADE 
glycaemic risk assessment diabetes equation, MAGE mean aplitude of glycaemic 






Z value P value
MBG 15.82 21.69 −1.639 0.101
SD 19.32 15.77 −0.990 0.322
CONGA* 14.55 23.85 −2.595 0.009
LI 20.55 13.69 −1.912 0.056
LBGI* 21.95 11.31 −2.970 0.003
GRADE 20.84 13.19 −2.136 0.033
MAGE 18.82 15.08 −1.045 0.296
M value* 21.36 12.31 −2.526 0.012
MAG 20.86 13.15 −2.151 0.031
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GRADE, MAGE, M value, and MAG (P < 0.0167); com-
paring with the hypoglycemia group, the MG is similar, 
but the insulinoma group has lower CONGA and higher 
LBGI and MAG (P < 0.0167).
Diagnostic indexes and the cut‑off point for insulinoma
There is significant difference in the glucose varia-
tion indexes, CONGA, LBGI, M value between the two 
groups, so these three indexes are considered as exam-
ined variable. Area under the ROC curve of LBGI, M, 
CONGA is 87.2, 81.8 and 77.3%, respectively. The LBGI 
cut-off point is 4.06, the corresponding sensitivity (with 
95% CI) is 90.9%, specificity (with 95% CI) 81.8%, with 
the Youden 73%; the M value cut-off point is 7.79, the 
corresponding sensitivity (with 95% CI) and specificity 
(with 95% CI) are both 81.8%, with the Youden 55%; the 
CONGA cut-off point is 4.38, the corresponding sen-
sitivity (with 95% CI) is 72.7%, specificity (with 95% CI) 
81.8%, with the Youden 55%. Based on the Youden and 
area under the ROC curve value, LBGI seems to be of the 
highest accuracy (see Fig. 1).
Discussion
Insulinoma, first described by Graham in 1927, originates 
from islet β cells, also known as islet β cell tumors, and 
has an occurrence rate of around 4/1,000,000. Unlike 
other pancreatic neuroendocrine tumors, most insu-
linomas are benign, the malignant ones only account for 
5–10% [4], and are commonly seen in single adenomas. 
Insulinoma often occurs to people from 40 to 50  years 
old with similar occurrences between men and women.
The diagnosis of insulinoma consists of the qualitative 
diagnosis and the topographic diagnosis. At present, the 
qualitative diagnosis, of which the main means is labora-
tory examination, prevails in confirming the diagnosis. 
The laboratory examination, including determining the 
blood glucose of hypoglycemia, determining simultane-
ously the serum insulin and the C-peptide, and carry-
ing out starvation test, aims at confirming the existence 
of hypoglycemia and that it is caused by the improper 
secretion of endogenous insulin, that is, when the plasma 
glucose concentration ≤2.80 mmol/L, the insulin concen-
tration >25 mIU/L, the Insulin Release Index (IRI) >0.3. 
The topographic diagnosis is dependent on the imaging 
examination and due to the small size of the tumor and 
the difficulty in diagnosis, it is mainly used to instruct the 
operations.
Comparing the general information of all subjects, 
it can be found out that for patients in the insulinoma 
group, the time from the onset of the disease to the con-
firmation of diagnosis is significantly longer than that for 
patients in the hypoglycemia group (P  <  0.01). In order 
to prevent the incidence of hypoglycemia during the long 
course, the patients with insulinoma frequently increase 
their diets and thus cause the rise of the BMI. Hence 
is the statistical significance in the differences against 
the patients in the hypoglycemia and control groups 
(P < 0.01).
The study demonstrates that the fasting blood glucose 
of patients with insulinoma is lower than that of patients 
with hypoglycemia, and the fasting insulin, the fasting 
C-peptide, and the fasting IRI of patients with insulinoma 
are higher than those of patients with hypoglycemia. The 
differences are of statistical significance. Similar to the 
findings of the study,  Han et  al. [5], in comparing the 
glucose metabolism indexes of patients with hypoglyce-
mia caused by various reasons, also discover that in the 
OGTT (oral glucose tolerance test), the differences of 
the fasting blood glucose, the fasting IRI and C-peptide 
indexes among the insulinoma group, the functional 
hypoglycemia group, the impaired glucose tolerance or 
diabetes group are of statistical significance. The crucial 
step in the current qualitative diagnosis of insulinoma is 
to monitor the hypoglycemia and simultaneously deter-
mine the IRI >0.3 when the plasma glucose <2.8 mmol/L. 
However, there are studies indicating that the possibility 
of insulinoma cannot be ruled out even if the IRI <0.3 [6], 
and in the study four people among the 22 patients with 
insulinoma are with the IRI  <0.3. Therefore, to provide 
more reference parameters for the qualitative diagnosis 
of insulinoma, it is better to combine with the determina-
tion of the fasting blood glucose, the fasting insulin, the 
fasting C-peptide and the calculation of respective IRI.
It is relatively easy to make a qualitative diagnosis of 
hypoglycemia when the symptom is demonstrated as typ-
ical Whipple’s triad. Clinically, however, the symptoms 
Fig. 1 Roc curve of LBGI, M value, CONGA for insulinoma diagnosis. 
MBG mean blood glucose, CONGA continuous overall net glycemic 
action, LBGI Low Blood Glucose Index
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of hypoglycemia for patients with insulinoma are more 
complicated and volatile, which include the non-specific 
autonomic nerve symptoms like profuse sweating, pal-
pitation and trembling, as well as the central nervous 
system disorders like insanity, behavioral abnormality, 
personality change, epilepsy, narcolepsy, lethargy, coma 
[7–10]. The chronic patients can even suffer a remarkable 
reduction of blood glucose without any clinical symp-
toms [11, 12]. According to the study of Ding Bo et  al. 
[13], more than half of the patients with insulinoma suffer 
from hypoglycemia at night and among the 22 patients 
with insulinoma in this study, there are 11 of them suf-
fering the lowest blood sugar at night. Governed by the 
vagus nerves, the symptoms of hypoglycemia at night 
are still more unconspicuous. The traditional fingerstick 
glucose monitor only provides snapshots of plasma glu-
cose, so reducing its reliability for quantification of hypo-
glycaemic episodes, especially at night. The traditional 
glucose examination is unable to discover the atypical 
hypoglycemia and the hypoglycemia at night timely. The 
continuous glucose monitoring system, however, can 
indirectly reflect the level of blood glucose by monitoring 
the glucose concentration of interstitial fluid of the sub-
cutaneous tissues with a glucose sensor. Capable of offer-
ing the information about the blood glucose in all day, its 
major advantages lie in the fact that it is able to find out 
the hyperglycemia and hypoglycemia that are beyond the 
reach of traditional glucose examination, such as post-
meal hyperglycemia and asymptomatic hypoglycemia at 
night, and it can define the time, frequency, and extent 
of hypoglycemia, making up for the deficiency of tradi-
tional glucose examination, and providing new clues to 
preliminary diagnosis [14]. The emergence of real-time 
continuous glucose monitoring system equipped with 
alarming functions for determining hyperglycemia and 
hypoglycemia, in particular, is beneficial to the diagnosis 
of insulinoma, especially the atypical cases. Studies show 
that CGMS contributes to increasing the detection rate 
of hypoglycemia and the asymptomatic ones in particular 
[15–17].  Han et  al. contend that the lowest blood glu-
cose detected by CGMS is of diagnostic value to insu-
linoma. In this study, there is also a marked difference of 
the lowest blood glucose between the insulinoma group 
and the hypoglycemia group and the lowest blood glu-
cose of patients in the former group is remarkably lower 
than that in the latter group of which the hypoglycemia 
is caused by other reasons. Due to the different occur-
rence mechanism of hypoglycemia, the patients with 
insulinoma have suffered more serious hypoglycemia out 
of the unstifling secretion of endogenous insulin. In addi-
tion, this study suggests that hypoglycemia is of vital dan-
ger to the patients with insulinoma because of the high 
number in occurrence, the seriousness in extent and the 
long period of disease, therefore it is imperative to have 
early diagnosis and early treatment.
Currently, foreign literatures have referred to such 
indexes as MG, SD, LI, HBGI/LBGI, GRADE, MAGE, M 
value, CONGA, MAG, and J-Index, which are correlated 
with and different from one another, and reflect vari-
ous aspects of the glucose level and glucose fluctuation 
based on different calculations. MAGE is considered to 
be the most comprehensive index for assessing GV in the 
past, but the calculation method of MAGE neglects the 
glucose rise or fall by less than 1 SD, so it only reflects 
the glucose fluctuation with relatively big amplitude and 
thereby is not quite objective; M value, with the ideal glu-
cose as the baseline, makes the logarithmic transforma-
tion of the glucose fluctuation deviating from the baseline 
and then takes the average, it is a calculation which puts 
more emphasis on the deviation of hypoglycemia; LBGI 
is similar to M value, analysing the frequency and extent 
of hypoglycemia through the mathematical processing 
of blood glucose values; whereas CONGA-n represents 
the standard deviation of all current monitoring results 
against the monitoring results n hours ago, and it can 
evaluate the glucose fluctuation within the day in an 
accurate way, thus being more objective than MAGE [18]. 
It is a calculation which puts more emphasis on the devi-
ation of hypoglycemia. This study suggests that although 
there are differences between patients with insulinoma 
and those with hypoglycemia caused by other reasons in 
SD and MAGE, they are not statistical enough, while the 
marked differences in CONGA, LBGI and M value are of 
statistical significance, therefore these are three indexes 
that are essential for making a clinical analysis of the glu-
cose fluctuation characteristics of patients overwhelmed 
by hypoglycemia. Their more exact and sensitive descrip-
tions of the extent and glucose fluctuation of hypogly-
cemia make it easier to tell clinically the insulinoma 
from hypoglycemia caused by other reasons. Based on 
the Youden and area under the ROC curve value, LBGI 
seems to be of the highest accuracy.
Because of the heterogeneity, the diagnosis and dif-
ferential diagnosis of hypoglycemia is very complicated, 
determined mainly on clinical features, insulin levels, 
onset time and several tests. Glucose profile is only one 
part of these tests, and has not been studied broadly. Our 
study maybe provide a new clue to the hypoglycemia, 
and might be useful to identify insulinoma. Our study 
also has some limitations. First, the accuracy of CGMS 
sensor is more effective in elevated glycemic levels than 
hypoglycemic state, so it requires more frequent calibra-
tion by fingerstick tests. In our study, 4–6 fingersticks per 
day are needed to calibrate the CGMS for every person. 
However, there is still a need for more intensive research 
efforts in the future to develop robust, highly precise and 
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specific CGMS, which will employ advanced algorithms 
to take into account the time lag between the concen-
tration of glucose in the blood and the interstitial fluid. 
Second, due to the limited sample number, large-scale, 
multi-center study needs to be carried out for assessing 
the CGMS diagnostic value.
Authors’ contributions
WG and JD conceived the study. WG and YL analyzed the data, wrote the 
first draft of the manuscript and revised the manuscript. All authors critically 
reviewed the manuscript. JD is the guarantor. All authors read and approved 
the final manuscript.
Author details
1 Department of Endocrinology, Chinese PLA General Hospital, No. 28 Fuxing 
Road, Haidian District, Beijing 100853, People’s Republic of China. 2 Depart-
ment of Internal Medicine, The Affiliated Hospital of Institute of Aviation 
Medicine, Beijing 100089, People’s Republic of China. 
Acknowledgements
The authors are grateful to all the authors of the studies included in the pre-
sent study and their study participants.
Competing interests
The authors declare that they have no competing interests
Availability of data and materials
All data generated or analysed during this study are included in this article.
Ethics approval and consent to participate
The study was conducted in accordance with the principles of the declaration 
of Helsinki and approved by the Ethics Committee of the Chinese PLA General 
Hospital. Written informed consent was obtained from each patient before 
enrollment.
Received: 10 November 2016   Accepted: 2 March 2017
References
 1. Service FJ, Dale AJ, Elveback LR, Jiang NS. Insulinoma: clinical and diag-
nostic features of 60 consecutive cases. Mayo Clin Proc. 1976;51:417–29.
 2. Halfdanarson TR, Rubin J, Farnell MB, Grant CS, Petersen GM. Pancreatic 
endocrine neoplasms: epidemiology and prognosis of pancreatic endo-
crine tumors. Endocr Relat Cancer. 2008;15:409–27.
 3. Hirshberg B, Livi A, Bartlett DL, Libutti SK, Alexander HR, Doppman JL, 
Skarulis MC, Gorden P. Forty-eight-hour fast: the diagnostic test for insu-
linoma. J Clin Endocrinol Metab. 2000;85:3222–6.
 4. Hirshberg B, Cochran C, Skarulis MC, Libutti SK, Alexander HR, Wood 
BJ, Chang R, Kleiner DE, Gorden P. Malignant insulinoma: spectrum of 
unusual clinical features. Cancer. 2005;104:264–72.
 5. Han J, Zhang F, Bao YQ, et al. Diagnostic value of parameters of glucose 
metabolism as screening tests for insulinoma. Natl Med J China. 
2010;90(16):1093–6.
 6. Liu M, Mu Y, Pan C. Advances in diagnosis and treatment of insulinoma. 
China J Pract Intern Med. 2006;26(22):1767–9.
 7. Suzuki K, Miyamoto M, Miyamoto T, Hirata K. Insulinoma with early-morn-
ing abnormal behavior. Intern Med. 2007;46:405–8.
 8. Maestri M, Monzani F, Bonanni E, et al. Insulinoma presenting as idi-
opathic hypersomnia. Neurol Sci. 2010;31:349–52.
 9. Kawasakia A, Suzukia K, Miyamotoa M, Miyamotob T, Yanagic K, Shimizuc 
M, Hirataa K. Disruptive nocturnal behavior due to insulinoma revealed 
by continuous glucose monitoring. Eur J Neurol. 2014;21:e46–7.
 10. Cryer PE. Mechanisms of hypoglycemia-associated autonomic failure and 
its component syndromes in diabetes. Diabetes. 2005;54:3592–601.
 11. Heller SR, Cryer PE. Reduced neuroendocrine and symptomatic 
responses to subsequent hypoglycemia after 1 episode of hypoglycemia 
in nondiabetic humans. Diabetes. 1991;40:223–6.
 12. Cryer PE. Hypoglycemia in diabetes: pathophysiological mechanisms and 
diurnal variation. Prog Brain Res. 2006;153:361–5.
 13. Ding B, Sun R, Shen Y, et al. Application of continuous glucose monitoring 
system to explore the blood glucose fluctuation model of insulinoma. 
China Med Herald. 2013;10(29):57–8.
 14. Munir A, Choudhary P, Harrison B, Heller S, Newell-Price John. Continu-
ous glucose monitoring in patients with insulinoma. Clin Endocrinol. 
2008;68:912–8.
 15. Maia FF, Araujo LR. Efficacy of continuous gluco tem (CGMS) to detect 
postprandial hyperglycemia and unrecognized hypoglycemia in type 1 
diabetic patients. Diabetes Res Clin Pract. 2007;75(1):30–4.
 16. Maia FF, Araujo LR. Efficacy of continuous glucose monitoring system 
to detect unrecognized hypoglycemia in children and adolescents with 
type 1 diabetes. Arg Bras Endocrinol Metabol. 2005;49(4):569–74.
 17. Hoi-Hansen T, Pedersen-Bjergaard U, Thorsteinsson B. Reproducibility and 
reliability of hypoglycaemic episodes recorded with continuous glucose 
monitoring system (CGMS) in daily life. Diabet Med. 2005;22:858–62.
 18. McDonnell CM, Donath SM, Vidmar SI, Werther GA, Cameron FJ. A novel 
approach to continuous glucose analysis utilizing glycemic variation. 
Diabetes Technol Ther. 2005;7:253–63.
